Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Race to deliver therapies directly to the heart

Race to deliver therapies directly to the heart

New Capabilities

FDA accepts Helix catheter review as BioCardia pursues parallel approval tracks for device and therapy

April 28th, 2026: Japanese Patent Allowed for Heart3D Fusion Imaging Software

Overview

BioCardia's campaign to win the first FDA clearance for a catheter that injects cell and gene therapies directly into heart muscle cleared a pivotal regulatory hurdle in March 2026. The U.S. Food and Drug Administration accepted the company's pre-submission package for the Helix Transendocardial Delivery Catheter, confirming it contains all the necessary elements for substantive review and scheduling a formal meeting for the second quarter of 2026. The Helix device, backed by safety and efficacy data from fifteen clinical trials, uses a small helical needle that anchors within the beating heart to precisely deliver therapeutic agents to damaged muscle tissue. CDRH will lead the review in consultation with CBER.

BioCardia is simultaneously pursuing two regulatory tracks. Alongside the Helix device review, the company submitted its CardiAMP Heart Failure trial data to the FDA in April 2026 and filed a request for a Q2 meeting to explore accelerated approval for CardiAMP—its therapy that uses a patient's own bone marrow cells to repair heart tissue. New echocardiography data presented at the Technology and Heart Failure Therapeutics conference in Boston in March 2026 showed the therapy reduces pathological left ventricular remodeling, a structural sign the heart is rebuilding rather than further deteriorating. The company ended 2025 with approximately $2.5 million in cash and no revenues, making the timing of regulatory decisions financially consequential.

Why it matters

Clearing the delivery device would unlock an entire generation of cardiac cell and gene therapies for the 6 million Americans living with heart failure.

Play on this story Voices Debate Predict

Key Indicators

15
Clinical trials supporting approval
BioCardia's FDA submission includes safety and efficacy data from fifteen controlled studies
425,147
Annual U.S. deaths involving heart failure
Heart failure contributed to nearly half of all cardiovascular deaths in 2022
11%
Cell retention with intramyocardial delivery
Direct injection retains nearly four times more cells than intracoronary delivery
47%
Reduction in heart death equivalents
BioCardia's CardiAMP therapy showed this reduction in phase 3 trial results

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Peter Altman
Peter Altman
Leading dual regulatory tracks for Helix catheter and CardiAMP therapy
 Simon Stertzer
Simon Stertzer
Founding contributor
 Amish Raval
Amish Raval
Presented late-breaking trial results at THT 2026

Organizations Involved

BioCardia, Inc.
BioCardia, Inc.
Biotechnology Company
FDA Q2 meetings scheduled for both Helix catheter review and CardiAMP accelerated approval; $2.5M cash at year-end 2025

BioCardia develops biotherapeutic delivery systems and cell therapies for cardiovascular disease, headquartered in San Carlos, California.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Accepted Helix pre-submission for substantive review; Q2 2026 meeting scheduled; reviewing CardiAMP accelerated approval request

The FDA regulates medical devices, drugs, and biologics in the United States, including cell and gene therapies for cardiac disease.
Biosense Webster
Biosense Webster
Medical Device Company (Johnson & Johnson)
Competitor with NOGA/MyoStar system

Biosense Webster develops cardiac mapping and ablation technologies, including the MyoStar injection catheter used in early cell therapy research.

Timeline

  1. Japanese Patent Allowed for Heart3D Fusion Imaging Software

    Corporate

    Japan allows BioCardia's patent covering its Heart3D Fusion Imaging software used for procedure planning and real-time navigation during CardiAMP procedures; BioCardia reports positive consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on a potential approval submission.

  2. BioCardia Files for FDA Meeting on CardiAMP Accelerated Approval

    Regulatory

    BioCardia submits CardiAMP HF clinical study data to FDA and requests a Q2 2026 meeting to discuss the accelerated approval pathway for the CardiAMP System in ischemic heart failure with reduced ejection fraction, under its Breakthrough Designation.

  3. BioCardia Reports 2025 Annual Results with $2.5M Cash

    Corporate

    BioCardia reports 2025 annual financial results: net loss of $8.2 million, R&D expenses of $5.0 million, zero revenues, and cash of approximately $2.5 million at year-end.

  4. FDA Accepts Helix Pre-Submission Package for Substantive Review

    Regulatory

    FDA accepts BioCardia's Helix Transendocardial Delivery Catheter pre-submission package, confirming it contains all necessary elements for substantive review; formal Q2 2026 review meeting scheduled; CDRH leads in consultation with CBER.

  5. CardiAMP Echocardiography Data Presented at THT Conference

    Clinical Trial

    Late-breaking echocardiography results from the CardiAMP HF trial presented at Technology and Heart Failure Therapeutics (THT) in Boston show cell therapy patients demonstrated statistically significant reductions in pathological left ventricular remodeling versus controls, particularly in the elevated-biomarker subgroup.

  6. FDA Pre-Submission Filed for Helix Catheter

    Regulatory

    BioCardia files Pre-Submission with FDA seeking approval of Helix Transendocardial Delivery Catheter, supported by data from 15 clinical trials under Breakthrough Designation.

  7. Two-Year Trial Results Show 47% Reduction in Deaths

    Clinical Trial

    BioCardia announces two-year outcomes from Phase 3 CardiAMP-HF study showing 47% relative risk reduction in heart death equivalents and improved quality of life.

  8. Phase 3 Trial Completed

    Clinical Trial

    BioCardia completes Phase 3 randomized double-blind controlled trial of autologous cell therapy for ischemic heart failure with 115 patients across 18 centers.

  9. FDA Approves Protocol Amendment

    Regulatory

    FDA approves CardiAMP Heart Failure II protocol amendment to use proprietary cell population analysis screening to define treatment.

  10. Positive Interim Phase 3 Results

    Clinical Trial

    BioCardia reports positive interim results from CardiAMP-HF trial showing 86% relative risk reduction in heart death equivalents in patients with elevated biomarkers.

  11. BioCardia Goes Public

    Corporate

    BioCardia becomes a publicly traded company through a reverse merger with Tiger X Medical.

  12. Early Transendocardial Injection Studies

    Research

    First clinical studies using catheter-based transendocardial injection of skeletal myoblasts in heart failure patients demonstrate feasibility of the approach.

  13. BioCardia Founded

    Corporate

    Dr. Simon Stertzer and colleagues establish BioCardia in San Carlos, California, to develop biointerventional cardiology technologies.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

FDA Approves First Cardiac Delivery Catheter, Unlocking New Therapies

The FDA clears the Helix catheter within 12-18 months following Pre-Submission alignment. As the first approved transendocardial delivery system, it becomes the standard platform for delivering emerging cell and gene therapies to the heart, opening a new commercial market. Multiple pharmaceutical companies license the technology for their cardiac therapy pipelines.

Discussed by: BioCardia investor communications, regenerative medicine analysts at CGT Live and Cardiac Interventions Today
Consensus —
2

FDA Requires Additional Clinical Data, Delaying Approval

The FDA's Pre-Submission feedback identifies gaps in the existing clinical data, requiring BioCardia to conduct additional studies or provide supplementary safety analyses. This extends the timeline by 2-3 years but maintains the pathway to eventual approval. The company's limited cash position becomes a critical factor.

Discussed by: Medical device regulatory consultants, FDA device approval process analysts
Consensus —
3

Competitor Reaches Market First with Alternative Delivery System

Another company—potentially a larger player like Biosense Webster or a well-funded competitor—accelerates development of a competing transendocardial or alternative delivery system, reaching FDA approval before BioCardia. This would diminish Helix's first-mover advantage and compress its market opportunity.

Discussed by: Cardiac device industry analysts, medical technology investors
Consensus —
4

Cardiac Gene Therapy Approval Creates Urgent Delivery Demand

One of the cardiac gene therapies currently in late-stage trials achieves FDA approval, creating immediate clinical need for a delivery mechanism. This external catalyst accelerates FDA review of the Helix catheter as an enabling technology, potentially through expedited review pathways.

Discussed by: Gene therapy developers, cardiology researchers at Circulation Research and Nature
Consensus —
5

BioCardia Runs Short on Cash Before FDA Decisions

With approximately $2.5 million in cash at year-end 2025, no revenues, and two simultaneous FDA review processes underway, BioCardia faces a narrow financing window. If regulatory meetings extend without approval or a partnership deal, the company may need to raise dilutive capital or seek a strategic acquirer. A funding gap would jeopardize both the Helix catheter and CardiAMP approval tracks simultaneously.

Discussed by: Medical device analysts and biotech investors tracking BCDA financial filings
Consensus —

Historical Context

First Autologous Stem Cell Heart Injection (2003)

June 2003

What Happened

French surgeon Philippe Menasché performed the first clinical injection of autologous skeletal myoblasts into human heart muscle using catheter-based delivery. Five patients with ischemic heart failure received cells via the MyoStar NOGA-guided catheter system. The procedure demonstrated feasibility but raised questions about arrhythmia risks.

Outcome

Short Term

The pilot study showed the approach was technically possible, with improvements in heart function observed at six-month follow-up.

Long Term

This pioneering work launched two decades of clinical trials exploring catheter-based cell delivery to the heart, establishing transendocardial injection as a viable approach despite ongoing safety refinements.

Why It's Relevant Today

BioCardia's Helix catheter represents the culmination of this 20+ year development arc—the first attempt to gain regulatory approval for a device category that has existed only in research settings.

Biosense Webster NOGA System Development (1997-2005)

1997-2005

What Happened

Biosense Webster developed the NOGA electromechanical mapping system with the MyoStar injection catheter, creating the first commercial platform for targeted intramyocardial injection. The system could construct three-dimensional heart maps and guide needle placement to specific regions of damaged tissue.

Outcome

Short Term

The technology enabled dozens of clinical trials investigating cell therapy for cardiac disease, establishing proof of concept for targeted delivery.

Long Term

While the NOGA/MyoStar system was never approved specifically as a therapy delivery device, it proved the technological foundation that BioCardia and others built upon.

Why It's Relevant Today

The Helix catheter is designed as a dedicated delivery system rather than a mapping tool with injection capability, representing a shift from research-focused devices to a commercial therapeutic platform.

REGENERATE Trials and Delivery Method Debate (2014-2022)

2014-2022

What Happened

The REGENERATE-IHD and REGENERATE-DCM trials directly compared intracoronary delivery (through coronary arteries) versus intramyocardial delivery (directly into heart muscle) in 60+ patients with chronic heart failure. Researchers sought to determine whether the technically simpler intracoronary approach could match the cell retention of direct injection.

Outcome

Short Term

Studies found intramyocardial injection retained about 11% of delivered cells versus 3% for intracoronary delivery—a significant difference for therapeutic efficacy.

Long Term

The data reinforced the clinical rationale for transendocardial delivery systems like Helix, demonstrating that the added procedural complexity produces meaningfully better cell retention.

Why It's Relevant Today

This body of evidence supports BioCardia's FDA application by showing that transendocardial delivery is not just one option among equals—it appears to be the superior approach for getting therapeutic cells where they need to go.

Sources

(14)
+8
GlobeNewswire Investing.com Heart Failure Society of America Journal of Cardiovascular Translational Research CGT Live BioCardia Journal of the American College of Cardiology Cardiovascular News BioSpace GlobeNewswire GlobeNewswire GlobeNewswire GlobeNewswire GlobeNewswire